Clobetasone Butyrate 0.05% Teikoku
Clobetasone Butyrate 0.05% Teikoku Uses, Dosage, Side Effects, Food Interaction and all others data.
Clobetasone Butyrate 0.05% Teikoku is under investigation for the treatment of Scleroderma. Clobetasone Butyrate 0.05% Teikoku has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
| Trade Name | Clobetasone Butyrate 0.05% Teikoku |
| Availability | Prescription only |
| Generic | Clobetasol |
| Clobetasol Other Names | Clobetasol |
| Related Drugs | Humira, Cosentyx, Dupixent, prednisone, doxycycline, methotrexate, betamethasone topical, Remicade, Stelara, cyclosporine |
| Type | |
| Formula | C22H28ClFO4 |
| Weight | Average: 410.907 Monoisotopic: 410.166015296 |
| Groups | Approved, Experimental, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Japan |
| Last Updated: | September 19, 2023 at 7:00 am |
Clobetasone Butyrate 0.05% Teikoku Disease Interaction
Moderate: diabetes, diaper rash, hyperadrenocorticism, infections, ocular toxicities
Innovators Monograph
You find simplified version here Clobetasone Butyrate 0.05% Teikoku
